

For additional information on this merger please visit <https://uk.allianzgi.com/merger-european-equity-income-fund>

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. YOUR HOLDING IN THE FUND WILL BE AFFECTED BY THE CONTENTS OF THIS CIRCULAR – PLEASE READ CAREFULLY

If there is anything in this document you do not understand or if you are in any doubt as to what action to take, you should consult your solicitor or accountant or a person authorised under the Financial Services and Markets Act 2000 (the “Act”) such as your stockbroker or financial adviser.

PROPOSAL FOR A SCHEME OF ARRANGEMENT FOR THE MERGER OF

Allianz European Equity Income Fund

into

Allianz UK Listed Equity Income Fund

(both sub-funds of Allianz UK & European Investment Funds)

Your attention is drawn to the letter from the Authorised Corporate Director of Allianz UK & European Investment Funds and to the information contained herein.

A notice convening an Extraordinary General Meeting of Shareholders (the “Meeting”) to be held on 17 September 2021 is set out in Appendix 3. **Whether or not you propose to attend the Meeting, you are requested to complete and return the Proxy Form enclosed with this document to Allianz Global Investors GmbH c/o Paragon Customer Communications, PO Box 1408, Sunderland, SR5 9QY in accordance with the instructions printed on it as soon as possible and in any event no later than 5.00 pm on 13 September 2021.**

Letter to shareholders in the Allianz European Equity Income Fund

A Class Shares (Acc) (ISIN GB00B613Y526)
A Class Shares (Inc) (ISIN GB00B613Y419)
C Class Shares (Acc) (ISIN GB00B613Y740)
C Class Shares (Inc) (ISIN GB00B613Y633)

16 August 2021

Dear Shareholders,

Proposed Scheme of Arrangement for the merger of the Allianz European Equity Income Fund (the “Merging Fund”) into the Allianz UK Listed Equity Income Fund (the “Absorbing Fund”) (the “Scheme”).

We are writing to you as a Shareholder in the Merging Fund, to inform you of a Proposal to merge the Merging Fund into the Absorbing Fund.

The purpose of this circular is to explain and seek your approval for the proposed merger.

1. Background

Allianz Global Investors GmbH (acting by its UK branch) (the “ACD”) constantly reviews the investment opportunities on offer to its investors to ensure that its products are meeting customer needs and objectives and to ensure that its funds are achieving performance expectations. As part of our review, we consider opportunities which, given current and future expectations of the financial markets, are likely to deliver the optimum return for investors based on performance, costs (including our own published Assessment of Value report) and appropriate level of risk. These reviews have been of particular importance during the rapid and profound changes in the global financial markets in the recent past.

Following our review we have concluded that the Allianz European Equity Income Fund has not been providing shareholders with value in terms of fees while performance has also been behind the comparator benchmark for some time – see performance table comparison on page 2. This accompanied with a shrinking investor base and assets under management means we believe the strategy will become unviable in the near future.

Therefore, the ACD would like to offer our investors the Allianz UK Listed Equity Income Fund (the Absorbing Fund) as the ACD believes this will offer better opportunities for long term income and capital growth. The Absorbing Fund is managed by our London based UK Equity team headed by our UK Equity Chief Investment Officer, Simon Gergel and is co-managed by Richard Knight. Between them they have a combined experience of nearly 40 years in managing investments successfully for our shareholders.

The below table shows the performance of the Absorbing Fund and the Merging Fund

	1 Year Return (cumulative)	3 Year Return (Annualised)	5 Year Return (Annualised)
Allianz European Equity Income A Acc	21.34	-1.60	4.81
Allianz European Equity Income A Inc	21.20	-1.77	4.53
Allianz European Equity Income C Acc	22.08	-0.72	5.76
Allianz European Equity Income C Inc	22.04	-0.58	5.63
Allianz UK Equity Income C Inc	38.72	5.20	8.88

The Absorbing Fund has consistently outperformed its Target Benchmark, the FTSE All Share Index in terms of total return (capital growth and income) and also in terms of yield and has outperformed dividend yield of the FTSE All Share for the last 5 years.

The Total Return and Yield data for the 5 last years of the Absorbing Fund is shown below.

Yearly Return					
	Yearly Return 2016	Yearly Return 2017	Yearly Return 2018	Yearly Return 2019	Yearly Return 2020
Allianz UK Listed Equity Income C Inc	7.97	15.07	-9.57	28.99	-7.74

FTSE AllSh TR GBP	16.75	13.10	-9.47	19.17	-9.82
FTSE AllSh Yld					

12 Month Yield					
	12 Mo Yield 12/2016	12 Mo Yield 12/2017	12 Mo Yield 12/2018	12 Mo Yield 12/2019	12 Mo Yield 12/2020
Allianz UK Listed Equity Income C Inc	4.06	3.94	5.21	4.59	3.76
FTSE AllSh TR GBP	3.80	3.67	3.95	4.38	4.67
FTSE AllSh Yld					

The fees you pay will be lower as a result of this merger as the Absorbing Fund has considerably lower fees than that of the Merging Fund as shown in section 2 below. The full fee schedule can also be found in Appendix 1.

For those investors who wish to continue their investment in a fund that targets income generating companies we consider the Scheme to be a favourable option. If the Proposal is approved at the Meeting, the Scheme will be implemented. If the Proposal is not approved at the Meeting, the Scheme will not be implemented. In such a case the ACD intends to take steps to close the Merging Fund.

Please go to our *website*

<https://uk.allianzgi.com/en-gb/forms-and-literature/legal-notices>

or *telephone us on 0800 073 2001* for more details on the Merging and Absorbing Funds as well as other funds available.

2. **Proposal on Offer**

The Absorbing Fund has been selected as it shares certain similarities with the Merging Fund. Both funds aim to achieve long-term capital growth, however it is an objective of the Absorbing Fund to generate a total return (income together with capital growth) greater than that of the FTSE All-Share Index (net of fees) over a rolling 5 year period. The Absorbing Fund also has a secondary objective to deliver an annual income yield greater than the FTSE All-Share Index. The Absorbing Fund invests mainly in securities listed on the London Stock exchange as represented in the FTSE

All-Share Index. Details of the respective investment objectives and policies of the Merging Fund and the Absorbing Fund are set out below at [Appendix 1](#).

Shareholders who currently hold Shares in the Merging Fund (whether these are A Class Shares or C Class Shares) will be issued with C Class Shares in the Absorbing Fund.

Holder of A Class Shares in the Merging Fund will move into C Class Shares in the Absorbing Fund. For these investors the Ongoing Charges will reduce from 1.93% p.a. which is currently payable on your A Class Shares down to 0.66% p.a., a saving of 1.27% p.a. based on the current Ongoing Charge of the Merging Fund.

Holders of C Class Shares in the Merging Fund will move into C Class Shares in the Absorbing Fund. The Ongoing Charge for current C Class Shareholders will reduce from 1.19% p.a. which is currently payable on your C Shares to 0.66% p.a., a saving of 0.53% p.a. based on the current Ongoing Charge of the Merging Fund.

The Absorbing Fund has a similar risk profile to your current investment and the Synthetic Risk and Reward Indicator (SRRI) will remain at 6.

The distribution payments you receive for the Absorbing Fund will be six monthly as opposed to the quarterly distribution payments that you currently receive in the Merging Fund. The six monthly payment dates will remain the same as they currently are, being 31 Dec (normally 31 Oct) and 30 April. Please see Appendix 1 for details.

Accordingly, we propose to merge the Merging Fund into the Absorbing Fund. Full details of the proposed changes are set out in [Appendix 1](#).

The purpose of this circular is to give you information on the Absorbing Fund, to set out proposals under which your investment in the Merging Fund may become an investment in the Absorbing Fund and to convene a Meeting at which you may consider and vote on the Proposal set out in this letter.

If the Merger is approved then your investment will be merged into the Absorbing Fund on 1 October 2021 (the Effective Date). At least 75% of the votes cast at the Meeting need to be cast in favour of the resolution for the Merger to become effective.

3. **Effects of Voting**

If the Proposal at the Meeting is approved, you will receive New Shares in the Absorbing Fund pursuant to the Scheme. If the Proposal is not approved, it is the intention of the ACD to wind up the Merging Fund.

Important – if the vote is successful, you will receive New Shares in the Absorbing Fund even if you have voted against the Merger or have not voted at all.

You may sell your Shares in the ordinary way or switch your Shares for C Class Shares of another sub-fund of the Company (other than the Absorbing Fund), before the 24 September 2021, the last day before the Effective Date.

See section “Helpful questions and answers” below for details of the UK tax implications of such sale or switching of your Existing Shares.

Shares sold before the Meeting will not be included in the vote on the Merger.

4. **Scheme**

If the vote at the Meeting is successful and the Merger is approved, it will be effected by way of the Scheme and the assets of the Merging Fund will be transferred to the Absorbing Fund and you will receive New Shares in the Absorbing Fund in place of those you currently hold in the Merging Fund, which will be cancelled.

It is intended that the proposed arrangements will constitute a scheme of reconstruction, and as such should not result in a disposal, for UK tax purposes.

The ACD has made a clearance application to HMRC in respect of certain aspects of the treatment of the proposed arrangements as a scheme of reconstruction and HMRC has notified the ACD that clearance has been granted. In addition, any allocation of income made as a result of the Scheme will be taxable in the normal way. Details of the UK tax implications of the proposed arrangements are set out in the section “Helpful questions and answers” below and details of the clearance application are set out in Appendix 4.

For the avoidance of doubt, investors who choose to redeem their investment will not benefit from the HMRC clearance and are likely to be treated as disposing of their Existing Shares for the purposes of UK capital gains tax and UK corporation tax on chargeable gains.

The technical details of the Scheme are set out in Appendix 2 and you are urged to read the terms under which the Merger will be implemented. You should seek your own independent professional advice in connection with the tax implications of the Scheme.

5. **Important Points to Consider**

- If the Merger goes ahead, you will be an investor in the Absorbing Fund and you will no longer be a Shareholder in the Merging Fund.
- The objective and investment policy of the Merging Fund and the Absorbing Fund are different, however they do share some similarities (see Appendix 1)
- We have compared the fees you are currently paying in the Merging Fund against those you will be paying in the Absorbing Fund. You will pay less than you are currently paying whichever class of shares you are currently in.

	Allianz European Equity Income Fund (the Merging Fund)	Allianz UK Listed Equity Income Fund (the Absorbing Fund)
Annual Management Charge	A Class of Shares 1.25% p.a. C Class of Shares 0.75 % p.a.	C Class of Shares 0.75 % p.a. (The AMC will be reduced to 0.60% on the Effective Date)

- C Class Shares of the Merging and Absorbing Funds are “clean fee” Shares and carry a lower Annual Management Charge than the A Class Shares of the Merging Fund. The Annual Management Charge for Allianz UK Equity Income Fund is charged to capital.
- The distribution payments you receive for the Absorbing Fund will be six monthly as opposed to the quarterly distribution payments that you currently receive in the Merging Fund. The six monthly payment dates will remain the same as they currently are, being 31 Dec (normally 31 Oct) and 30 April

Conditions

For the Merger to become effective, Shareholders are required to pass an Extraordinary Resolution set out in the Notice of Meeting which appears in Appendix 3.

If the Extraordinary Resolution is passed by the Required Majority, and the other conditions referred to below are satisfied, the Scheme will proceed and become effective on the Effective Date and will be binding on all Shareholders in the Merging Fund whether or not they have voted in favour of it or voted at all. If an Extraordinary Resolution is not passed then the Merger will not proceed and then we will formally write to you to in order to close the Merging Fund.

6. Dealings in Shares

Subscriptions in the Merging Fund will not be suspended, including those made on a regular basis by direct debit. Subscriptions in the Merging Fund shall be possible until the business day prior to the Effective Date.

If the Merger is approved, dealings in the Shares in the Merging Fund will cease at 12 noon on 24 September 2021. Instructions received by the ACD after this time will be treated as instructions for dealings in New Shares in the Absorbing Fund.

The ACD believes that the Proposal is in the best interest of the Shareholders. However, in the event that you do not wish to receive Shares in the Absorbing Fund, you may sell your Shares in the Merging Fund (or switch your investment into the C Class Shares of another fund of the Company, free of any initial charge) prior to the last day of dealing in the Merging Fund (before 12 noon on 24 September 2021).

Please contact 0800 073 2001 for more details on the other funds available. If you wish to switch to another fund, we must have received your instructions prior to the last day of dealing in the Merging Fund (before 12 noon on 24 September 2021).

Contract notes will not be sent out in respect of New Shares in the Absorbing Fund issued under the terms of the Scheme. However, Shareholders will be sent a letter of notification confirming the New Shares in the Absorbing Fund to which they have become entitled within ten business days of the Effective Date (by 14 October 2021).

Shareholders will be able to deal in their New Shares in the Absorbing Fund on 4 October 2021 in accordance with the normal procedures for dealing in the Absorbing Fund.

7. **Share Classes**

There are currently A Class Shares and C Class Shares in issue in the Merging Fund. If the Merger is approved, the Shareholders of both A Class Shares and C Class Shares in the Merging Fund will be issued with C Class Shares in the Absorbing Fund.

The Merging Fund and the Absorbing Fund both have accumulation and income shares in issue. Therefore if you currently hold either A (Acc) Class Shares or C (Acc) Class Shares, you will be issued with C (Acc) Class Shares in the Absorbing Fund and if you currently hold either A (Inc) Class Shares or C (Inc) Class Shares, you will be issued with C (Inc) Class Shares in the Absorbing Fund.

No initial (or other) charge will be made in respect of Shares issued under the Scheme. Shares in the Merging Fund will be cancelled immediately after the Merger becomes effective and will thereafter cease to have any value.

8. **Expenses**

All the administrative costs and expenses relating to the implementation of the Merger described in this document will be paid by the ACD. These include the costs of preparing and implementing the Merger, the costs of holding the Meeting (and any adjourned Meeting) and of terminating the Merging Fund following the Merger (if the Proposals are approved).

The costs of restructuring the portfolio in preparation for the Scheme of Arrangement will be borne by the Merging Fund. The costs for repositioning the Merging Fund have been estimated to be no more than 0.48%.

9. **ISAs**

Shares in the Absorbing Fund will be eligible to be held in an ISA in the same way that the Shares in the Merging Fund are. Your ISA wrapper will remain in place.

10. **Regular savers**

Investments made by regular savers in the Merging Fund will continue until 12 noon on 24 September 2021. If you are a regular saver, your regular savings instructions will be transferred to the Absorbing Fund to allocate your future savings. This will be done free of charge. Please notify the ACD should you wish to switch your monthly payment into one or more of our other funds or to terminate your regular savings plan. You will need to inform the ACD of your decision before 12 noon on 24 September 2021.

You can find details of our full range of funds on our website <https://uk.allianzgi.com/B2C> for retail investors, for IFA's please visit <https://uk.allianzgi.com/Adviser>. to help you make your selection. If you require further advice you should contact your usual financial advisor.

11. **Accounting dates**

Final accounts in respect of the Merging Fund will be prepared for the period up to the Effective Date. Where an allocation of income is made, a tax voucher will be despatched to Shareholders in relation to this final period.

12. **Consents**

The consents and approvals in relation to the Merger and the Scheme are set out in Appendix 4.

13. **Documentation Available**

The prospectus of the Company including details of the Absorbing Fund is available upon request during normal business hours by contacting us on telephone number 0800 073 2001 or via the website <https://uk.allianzgi.com/B2C> for retail investors, for IFA's please visit <https://uk.allianzgi.com/Adviser..>

The Key Investor Information Document ("KIID") for the New Shares is enclosed with this circular. This document contains important information about the investment policy and risk profile of the Absorbing Fund. You should therefore read the KIID carefully.

14. **Action to be taken**

You are urged to vote, either in person or by proxy, for or against the Extraordinary Resolution to be proposed at the Meeting.

It is important that you exercise your voting rights by completing and returning the enclosed Proxy Form to the ACD sufficiently in advance for it to arrive prior to 5.00 pm on 13 September 2021. Returning a Proxy Form does not affect your right to attend and vote in person should you then so decide.

You can return your signed Proxy Form by post to Allianz Global Investors GmbH, c/o Paragon Customer Communications, PO Box 1408, Sunderland, SR5 9QY using the enclosed pre-paid envelope or by emailing a scanned copy to: investor.services@allianzgi.com.

If you require any further information concerning this circular, please contact us on tel: 0800 073 2001.

As mentioned on the front of this document, if there is anything concerning the Proposal that you do not understand or if you are in doubt as to what action to take, you should consult your usual professional adviser.

Yours faithfully

Authorised Signatory

Allianz Global Investors GmbH (acting by its UK branch)

TIMETABLE FOR PROPOSALS

26 July 2021	Share register cut-off for qualifying Shareholders
16 August 2021	Details posted to Shareholders on the register
5.00 pm 13 September 2021	Deadline for receipt of Proxy Forms
12 noon 17 September 2021	Meeting of Shareholders

IN THE EVENT OF A YES VOTE AT THE MEETING OF SHAREHOLDERS

Implementation

12 noon 24 September 2021	Last day of dealing for the Merging Fund.
27 September 2021	Period of repositioning for the Merging Fund commences.
1 October 2021	Planned Effective Date for the Merger. The final valuation point will be at 12 noon to ensure consistency with the valuation of the Absorbing Fund.

Post-Implementation

4 October 2021	First day of dealing in the Absorbing Fund following the Merger
----------------	-----------------------------------------------------------------

Letters notifying Shareholders of the issue of New Shares in the Absorbing Fund will be posted to Shareholders within ten business days of the Effective Date, by 14 October 2021.

In the event the Quorum is not reached at the Meeting of Shareholders on 17 September 2021 the meeting will be adjourned and the following revised timetable will apply to the Scheme:

12 noon 24 September 2021	Adjourned Meeting of Shareholders
12 noon 1 October 2021	Last day of dealing for the Merging Fund
8 October 2021	Planned Effective Date for the Merger if the Meeting of Shareholders is adjourned

The ACD and Depositary may decide that the Effective Date should be other than 1 October 2021. Should this happen, consequential amendments may be made to some of the dates above.

Helpful questions and answers

Why have I received this circular?

You have received this circular because you held Shares in the Merging Fund on 26 July 2021 and so are entitled to vote on the resolution affecting the Merging Fund at the Meeting on 17 September 2021. Please note that the votes attaching to any Shares sold between 27 July 2021 and 17 September 2021 will be ignored.

Why is a Meeting being held?

The ACD is proposing a resolution to approve the Proposals to merge the assets of the Merging Fund into the Absorbing Fund. The Merger requires approval by Shareholders. Shareholders are being asked to consider and vote on the Merger at a Meeting convened for 17 September 2021. Shareholders may vote in person or by proxy at the meeting or by completing and returning the Proxy Form enclosed with this circular.

How will Shareholder approval be obtained for the Merger?

At least 75% of the votes cast at the Meeting need to be in favour of the Merger in order for the Merger to be approved so it is important that all Shareholders vote. To ensure your views are reflected you are requested to complete and return the enclosed Proxy Form whether or not you intend to attend the Meeting. Completing and returning the Proxy Form does not prevent you from attending the meeting in person and voting if you wish.

How do I vote?

Whether or not you intend to be present at the Meeting please complete and return the enclosed Proxy Form to be received by 5.00 pm on 13 September 2021 in the pre-paid envelope provided. Please ensure that the Proxy Form is signed by at least one registered Shareholder. Duplicate Proxy Forms for the same Shares will be disregarded. Completion and return of the Proxy Form will not preclude you from attending and voting at the Meeting (and any adjourned Meeting) in person if you wish to do so.

What is the Proxy Form?

The Proxy Form enclosed with this circular allows you to vote on the resolution to be proposed at the Meeting on 17 September 2021. You may vote in favour or against the resolution to approve the Merger of the Merging Fund into the Absorbing Fund. Even if you complete and return a Proxy Form, you may still attend and vote at the Meeting.

What happens if I do nothing and do not return a Proxy Form?

If you do nothing and do not return a Proxy Form and the Merger is approved your Existing Shares will be subject to the Merger due to be implemented on 1 October 2021. You will receive New Shares in the Absorbing Fund in place of your Existing Shares. You will no longer hold Shares in the Merging Fund.

If the Merger is not approved, you will retain your Shares in the Merging Fund.

What is the “scheme of arrangement” (“Scheme”)?

The Scheme in Appendix 2 sets out the proposed terms of and processing arrangements for the Merger. In summary, if the Merger is approved, Shareholders in the Merging Fund will receive New Shares in the Absorbing Fund. The Absorbing Fund will issue New Shares to the value of the assets it receives from the Merging Fund and these will be allocated to the Merging Fund’s Shareholders in proportion to their investment in the Merging Fund.

The Scheme is intended to be structured so that, if the Merger is approved, the Scheme will apply to all Shares in the Merging Fund of the relevant Class and not just the Shares of those Shareholders in the Merging Fund that vote in favour of the Merger and it is intended that the exchange of Shares for New Shares pursuant to the Scheme should not be treated as a disposal for UK capital gains tax, or corporation tax on chargeable gains, purposes.

What if I sell my Existing Shares before the Meeting?

Shares sold before the Meeting will not be included in the vote on the Merger.

Are there any tax implications as part of the proposed changes?

The ACD intends that the proposed arrangements between the Merging Fund and the Shareholders of each Class of Existing Shares, whereby the Absorbing Fund issues C Class Shares to Shareholders in the Merging Fund in respect of and in proportion to their holdings of Existing Shares of the relevant Class and such Existing Shares are cancelled, will constitute a scheme of reconstruction for UK capital gains tax, or corporation tax on chargeable gains, purposes. If they are each treated as a scheme of reconstruction, such proposed arrangements should not result in a disposal for UK tax purposes. The ACD has made a clearance application to HMRC in respect of certain aspects of the treatment of the proposed arrangements as a scheme of reconstruction and HMRC has notified the ACD that clearance has been granted. Details of such clearance application are set out in

Appendix 4. Based on the ACD's understanding of the relevant UK tax legislation and the clearance obtained from HMRC, New Shares in the Absorbing Fund issued to Shareholders as a result of the Merger and pursuant to the Scheme should be deemed to have the same acquisition date and cost for the purposes of UK capital gains tax and corporation tax on chargeable gains as their Existing Shares in the Merging Fund, provided such arrangements constitute a "scheme of reconstruction".

Any allocation of income made as a result of the Scheme will be taxable in the normal way.

Shareholders should note that there can be no guarantee that the proposed arrangements, if approved, will be treated as a scheme of reconstruction or qualify for no disposal treatment for UK capital gains tax and corporation tax on chargeable gains purposes. The information provided above, which is based on current UK tax legislation and what is understood to be the current practice of HMRC as at the date of this circular, does not constitute, and is not a substitute for, tax advice. Shareholders should consult their own advisers on the tax implications of all of the proposed arrangements.

What are the costs of the Proposals and who will cover these costs?

All the administrative costs and expenses relating to the implementation of the Merger described in this document will be paid by the ACD. These include the costs of preparing and implementing the Merger, the costs of holding the Meeting (and any adjourned Meeting) and of terminating the Merging Fund following the Merger (if the Proposals are approved).

Transfers of Shares, or agreements to transfer such Shares, pursuant to the Scheme should not be subject to UK stamp duty reserve tax or stamp duty.

Do I have any cancellation rights following the issue of any New Shares?

Please note that you will not have cancellation rights in respect of the New Shares which are issued to you under the Merger. Under the provisions of the FCA Conduct of Business Sourcebook, cancellation rights may apply to subsequent purchases of Shares in the Absorbing Fund.

What if I do not want to receive Shares in the Absorbing Fund in place of my Shares in the Merging Fund?

If you do not want to receive New Shares in the Absorbing Fund we recommend that you do one of the following:

- A. sell your Existing Shares before 12 noon on the last dealing day before the Effective Date planned for 1 October 2021;
- B. contact the ACD and arrange for your Shares to be switched into C Class Shares of another sub-fund of the Company other than the Absorbing Fund. You will not be charged a fee for this switch. If you wish to switch out of the Merging Fund you must do so before 12 noon on the last dealing day before the Effective Date on 24 September 2021.

Please note that the sale of your Shares or the switch of your Shares to another sub-fund of the Company is likely to be regarded as a disposal for UK capital gains tax, or corporation tax on chargeable gains, purposes, unless they are held within an ISA wrapper. If you are in any doubt about your tax position or potential tax liability you should seek professional advice.

Who can advise me on how to vote?

This mailing is intended to provide Shareholders with the information needed to assess the proposed Merger. Shareholders requiring advice on the suitability of the Absorbing Fund for their investment purposes will need to consult a financial adviser. The ACD is not able to give investment advice based on individual circumstances.

Will there be any changes to the contact, dealing and other arrangements for my Shares?

There will be no changes to your normal dealing, contact and account administration arrangements. Differences in product features are explained in Appendix 1.

APPENDIX 1: DETAILS OF THE ABSORBING FUND AND COMPARISON WITH THE MERGING FUND

MERGING FUND	ABSORBING FUND
Investment Objective	
<p>The objective of the Fund is to achieve high and increasing income together with capital growth.</p>	<p>The primary investment objective of the Allianz UK Listed Equity Income Fund is to generate a total return (income together with capital growth) net of fees greater than that of the FTSE All-Share Index, over a rolling 5 year period.</p> <p>The Fund also has a secondary objective to deliver an annual income yield greater than the FTSE All-Share Index,</p> <p>Investors should be aware that the Fund's capital is at risk and there is no guarantee that the Fund will achieve its investment objective over the above period or at all.</p>
Investment Policy	
<p>The ACD aims to achieve the investment objective by investing mainly in securities listed on a Continental European stock exchange although it may invest internationally.</p> <p>It is the general intention of the ACD to invest in securities which offer above average current dividend yield or, if not, the prospect of superior long term capital growth.</p> <p>The ACD may also utilise deposits in the management of the portfolio. The Fund may also invest in collective investment schemes.</p>	<p>The ACD will invest at least 80% of the Fund's assets in securities listed on the London Stock Exchange as represented in the FTSE All-Share Index.</p> <p>Up to 20% of the Fund's assets may be invested outside of this index, either in the UK or internationally and in all economic sectors. It is the general intention of the ACD to invest in shares which offer above average current dividend income yield or, if not, the prospect of superior long term dividend growth. Therefore, it is not intended that the Fund will have similar weightings to the FTSE All-Share Index. Up to 10% of the Fund's investments may be held in convertibles and investment trust income shares in order to enhance the income yield.</p> <p>The ACD may also utilise deposits and money market instruments in the management of the portfolio, and together with money market funds, these may make up to a maximum of 10% of the Fund's assets. In addition, up to 5% of the Fund's assets may be invested in warrants.</p> <p>The Fund may also invest up to a maximum of 10% of the Fund's assets in other collective investment schemes including those managed by Allianz Global Investors and its group of companies.</p> <p>It must be noted that from time to time the Fund will also invest in securities and money market instruments that are offered within the scope of Initial Public Offerings on a recognised stock exchange or in another regulated market as set out in the Prospectus.</p> <p>The ACD may use derivatives for efficient portfolio management for the purposes of generating additional income (for example by writing covered call options up to</p>

	20% of the Net Asset Value of the Fund) and for hedging purposes.
Constitution	
Open-ended Investment Company	Open-ended Investment Company
Scheme Type	
UCITS Scheme	UCITS Scheme
Management and Administration	
ACD: Allianz Global Investors GmbH (acting by its UK branch) Depositary: State Street Trustees Limited	ACD: Allianz Global Investors GmbH (acting by its UK branch) Depositary: State Street Trustees Limited
Investment Powers and Restrictions	
Restrictions applicable to a UCITS scheme under the FCA Rules. Note that further restrictions are also set out in the Prospectus (in particular a 5% limit on warrants). In addition, the Merging Fund does not take advantage of the full UCITS scheme powers which are available under the FCA Rules in relation to the use of Derivatives. Please refer to Appendix III Part I of the Prospectus for more details on the investment management and borrowing powers of the Merging Fund.	Restrictions applicable to a UCITS scheme under the FCA Rules. Note that further restrictions are also set out in the Prospectus (in particular a 5% limit on warrants). In addition, the Absorbing Fund does not take advantage of the full UCITS scheme powers which are available under the FCA Rules in relation to the use of Derivatives. Please refer to Appendix III Part I of the Prospectus for more details on the investment management and borrowing powers of the Absorbing Fund.
Charges and Expenses	
Initial Charge: <ul style="list-style-type: none"> A Class Shares: None C Class Shares: None Annual Management Charge: <ul style="list-style-type: none"> A Class Shares: 1.25% p.a. C Class Shares: 0.75%p.a. Ongoing Charges <ul style="list-style-type: none"> A Class Shares: 1.93% C Class Shares: 1.19% Other fees and expenses are set out in the Prospectus in the section entitled "Fees and Expenses".	Initial Charge: <ul style="list-style-type: none"> C Class Shares: None Annual Management Charge: <ul style="list-style-type: none"> C Class Shares: 0.60% p.a. (The AMC will be reduced to 0.60% p.a. on the Effective Date) Estimated Ongoing Charges <ul style="list-style-type: none"> C Class Shares: 0.66% Other fees and expenses are set out in the Prospectus in the section entitled "Fees and Expenses".
Minimum Investment	
A Class Shares: £500	C Class Shares: £500

C Class Shares: £500	
Minimum Redemption	
A Class Shares: £250 C Class Shares: £250	C Class Shares: £250
Regular Savings	
A Class Shares: £50 C Class Shares: £50	C Class Shares: £50
Classes of Shares	
A Class Shares (income) A Class Shares (accumulation) C Class Shares (income) C Class Shares (accumulation)	C Class Shares (income) C Class Shares (accumulation) C Class Shares (income) C Class Shares (accumulation)
Income Allocation Dates	
Income Shares: 31 August – final, 30 November – interim, 28 February (29 February in a leap year) – interim and 31 May – interim Accumulation Shares: 31 August – final, 30 November – interim, 28 February (29 February in a leap year) – interim and 31 May – interim	Income Shares: 31 August – final, and 28 February (29 February in a leap year) – interim Accumulation Shares: 31 August – final, and 28 February (29 February in a leap year) – interim
Income Payment Dates	
Income Shares: 31 December (normally by 30 September) – final, 31 December – interim, 31 March – interim and 30 June – interim Accumulation Shares: 31 December (normally by 30 September) – final, 31 December – interim, 31 March – interim and 30 June – interim	Income Shares: 31 December (normally 31 October) – final, and 30 April – interim Accumulation Shares: 31 December (normally 31 October) – final, and 30 April – interim
Synthetic Risk and Reward Indicator	
A Class Shares: 6 C Class Shares: 6	C Class Shares: 6
Pricing	
Net Asset Value per Share The valuation point for the Merging Fund is 12 noon on a Dealing Day.	Net Asset Value per Share The valuation point for the Absorbing Fund is 12 noon on a Dealing Day.
Dealing	
Shares may be bought and sold daily.	Shares may be bought and sold daily.

The dealing cut-off point on any Dealing Day for the Merging Fund is usually 12 noon.	The dealing cut-off point on any Dealing Day for the Absorbing Fund is usually 12 noon.
Risks	
<p>There are additional risks associated with an investment in the Absorbing Fund and these have been discussed in the background and in the Proposal that you may experience in relation to the Merging Fund. The Absorbing and the Merging Fund may be subject to the following risks, as detailed in section "Risk Factors" of the Prospectus:</p> <p>Effect of Initial Charge or Redemption Charge; Dilution Levy; Suspension of Dealings in Shares; Liabilities of the Company; Currency Exchange Rates; Investment in Smaller Companies; Liquidity Risk; Interest Rate Risk; Investment in Emerging Markets; Derivatives; Specific Risks linked to EPM Techniques and Taxation.</p> <p>We would advise you to carefully read the section of the Prospectus entitled "Risk Factors", which is applicable to both the Merging and the Absorbing Funds, and the risk and reward profile of the C Class Shares of the Absorbing Fund which is set out in the KIID of the Absorbing Fund.</p> <p>The Prospectus is available for inspection (i) during usual business hours on any business day at the offices of Allianz Global Investors GmbH (acting by its UK branch) at 199 Bishopsgate, London EC2M 3TY; or (ii) on the internet at https://uk.allianzgi.com/B2C for retail investors, for IFA's please visit https://uk.allianzgi.com/Adviser.</p> <p>The KIID for the C Class Shares of the Absorbing Fund is enclosed with this circular.</p>	
Documentation	
<p>Certificates are not issued.</p> <p>Contract notes are issued to confirm transactions.</p> <p>Individual Shareholder statements are issued within 21 days of 5 January and 5 September of each year.</p>	<p>Certificates are not issued.</p> <p>Contract notes are issued to confirm transactions.</p> <p>Individual Shareholder statements are issued within 21 days of 5 January and 5 September of each year.</p>
Reports	
Annual and half-yearly reports for the Merging Fund are published by 31 December and 30 April respectively.	Annual and half-yearly reports for the Absorbing Fund are published by 31 December and 30 April respectively.

APPENDIX 2: SCHEME OF ARRANGEMENT

1. **Definition and interpretation**

- 1.1 The definitions set out in the Glossary (Appendix 5) apply to this Scheme.
- 1.2 References to paragraphs are to paragraphs set out in this Appendix 2.
- 1.3 If there is any conflict between the Scheme and the Instrument or Prospectus, then the Scheme will prevail. In the event of conflict between the Scheme and the FCA Rules, then the FCA Rules will prevail.
- 1.4 This Scheme will apply only where the Merger Proposals have been approved by the Shareholders.

2. **The Merger and required Shareholder Approval**

- 2.1 Shareholders are being asked to approve the Merger of the assets of the Merging Fund into the Absorbing Fund, the details of which are set out in Appendix 1.
- 2.2 Implementation of the Merger is conditional on Shareholders approving the Merger at the Meeting by the Required Majority voting in favour of the Merger and passing the Extraordinary Resolution and authorising and instructing the ACD and the Depositary to implement the Merger.
- 2.3 If the Merger is approved, the terms of the Scheme will be binding on all Shareholders, whether or not they vote in favour of it or vote at all. The Merger will be implemented as set out in paragraphs 4 onwards.
- 2.4 For the avoidance of doubt, if the Merger is not approved, it will not proceed.

3. **Suspension of dealings in the Merging Fund**

- 3.1 Redemption and subscription dealing in Existing Shares will be possible until the business day prior to the Effective Date.
- 3.2 If Shareholders wish to redeem Existing Shares, they will need to do so before 12 noon on 24 September 2021 and ensure they have requested the redemption of their Existing Shares by telephoning the Administrators on 0800 073 2001 or requesting the redemption in writing in the usual way.
- 3.3 The Effective Date of the Scheme is expected to be 1 October 2021.

4. **Income allocation arrangements**

- 4.1 The current accounting period of the Merging Fund will end at 12:00 noon on the Effective Date.
- 4.2 Income accruing to Shares in the Merging Fund in respect of the current accounting period to the Effective Date shall be accumulated and transferred to the capital account of the relevant Class of Shares of the Merging Fund and allocated to the C Class of Shares of the Absorbing Fund. The income so allocated shall be despatched to Shareholders in the form of a tax voucher in relation to this final period.

5. **Calculation of the Value of the Merging Fund and the Absorbing Fund**

- 5.1 The Value of the Existing Shares shall be calculated in accordance with the Instrument on a mid-price basis at 12 noon on the Effective Date less the Retained Amount.
- 5.2 The Value of the Shares in the Absorbing Fund shall be calculated in accordance with the Instrument on a mid-price basis at 12 noon on the Effective Date.

5.3 These Values will be used to calculate the number of New Shares to be issued to each Shareholder under paragraph 7 using the Share price determined.

6. Transfer of property and issue of New Shares in the Absorbing Fund

6.1 As at 12.01 p.m. on the Effective Date, the Depositary will cease to hold the transferred property as scheme property of the Merging Fund and will instead hold the transferred property as scheme property of the Absorbing Fund. The Depositary will make or ensure the making of any transfers or redesignations which may be necessary as a result of it ceasing to hold the transferred property as scheme property of the Merging Fund. The transferred property will be full payment for the New Shares issued to Shareholders, who will be treated as exchanging their Existing Shares for New Shares.

6.2 As at 12.01 p.m. on the Effective Date, the ACD will issue New Shares to Shareholders who are registered on the Effective Date as holding Existing Shares in the Merging Fund.

6.3 All Existing Shares in the Merging Fund will be cancelled and will cease to be of any value immediately following 12.01 p.m. on the Effective Date.

7. Basis for the issue of New Shares

7.1 New Shares will be issued to each Shareholder in the Merging Fund in proportion to the value of that Shareholder's individual entitlement to the Merging Fund's Value as at 12 noon on the Effective Date.

7.2 The value of each Shareholder's holding in the Absorbing Fund immediately after the Merger should be the same as the value of their holding in the Merging Fund immediately before the Merger but prices of Existing Shares and New Shares may not be identical and, accordingly, Shareholders are likely to receive a different number of New Shares under the Scheme to the number of Shares they currently hold.

7.3 The number of New Shares to be issued to each Shareholder will (if necessary) be rounded up to the nearest one-hundredth of a New Share at the ACD's expense (which will, as soon as practicable after the Effective Date, accordingly pay into the Absorbing Fund an amount equal to the value of the additional New Shares issued as a result of the rounding up).

7.4 Shareholders who currently hold Shares in the Merging Fund (whether these are A Class Shares or C Class Shares) will be issued with C Class Shares in the Absorbing Fund.

7.5 The formula used in calculating a Shareholder's entitlement to New Shares in the Absorbing Fund will be available on request.

8. Notification of the New Shares issued under the Scheme

8.1 It is intended that the ACD will despatch notification of the Class, type, and number of New Shares issued to each Shareholder within ten business days of the Effective Date (by 14 October 2021).

8.2 Transfers, redemptions or switches of New Shares issued under the Scheme may be effected from the next business day after the Effective Date (expected to be 4 October 2021) in accordance with the terms and conditions of the Absorbing Fund.

8.3 Account numbers will remain the same and should be quoted when enquiring about an account.

9. Termination of the Merging Fund

9.1 If the Scheme is approved by the Shareholders, the ACD will notify the FCA of such approval and, following the Merger, will terminate the Merging Fund in accordance with the terms of the Scheme and the FCA Rules.

- 9.2 The Retained Amount and any income arising on it shall continue to be held as property of the Merging Fund, and will be used by the Depositary to pay outstanding liabilities of the Merging Fund in accordance with the provisions of the Scheme, the Instrument, the Prospectus and the FCA Rules.
- 9.3 If, on completion of the termination, there are any surplus monies remaining in the Merging Fund, they, together with any income arising, less any shortfall on the Merging Fund not recoverable from the Absorbing Fund in accordance with paragraph 9.4, shall be transferred to the Absorbing Fund. No further issue of New Shares shall be made as a result. The Depositary shall then cease to hold the relevant Retained Amount as scheme property of the Merging Fund and shall hold it as scheme property of the Absorbing Fund and shall make such transfers and redesignations as may be necessary as a result.
- 9.4 If the Retained Amount and any income arising from it is insufficient to discharge all the liabilities of the Merging Fund, the Depositary will, where permitted under the FCA Rules, pay the amount of the shortfall out of the scheme property attributable to the Absorbing Fund. This will only occur if the ACD, after consulting the Depositary of the Absorbing Fund, is of the opinion that proper provision was made for meeting such liabilities as were known or could reasonably have been anticipated at the time of the transfer.
- 9.5 The Depositary will then request the FCA to approve the termination of the Merging Fund.
- 9.6 On completion of the termination, the ACD and the Depositary will be discharged from all their obligations and liabilities in respect of the Merging Fund, except those arising from any breach of duty before that time.

10. **Charges and Expenses**

- 10.1 The ACD and the Depositary will continue to receive their usual fees and expenses for being ACD and Depositary respectively of the Merging Fund out of the property of the Merging Fund until the Effective Date.
- 10.2 The costs of convening and holding the Meeting shall be borne by the ACD. Any redesignation or registration costs and any UK stamp duty or equivalent overseas taxes or duties payable in respect of the Scheme shall be borne by the Merging Fund.
- 10.3 The ACD shall not levy any initial charge in respect of the New Shares in the Absorbing Fund created and issued pursuant to the Scheme. The cost of terminating the Merging Fund shall be borne by the ACD.

11. **The ACD and the Depositary to rely on the Register and Certificates**

The ACD and the Depositary shall each be entitled to assume that all information contained in the register of Shareholders of the Company on and immediately prior to the Effective Date is correct, and to utilise the same in calculating the number of New Shares in the Absorbing Fund to be issued and registered pursuant to the Scheme.

12. **Alterations to the Scheme**

- 12.1 The ACD and the Depositary may agree that the Effective Date is to be other than 1 October 2021, in which case certain adjustments may be made to the other elements in the timetable of the Scheme as the ACD and the Depositary consider appropriate.
- 12.2 There may be circumstances beyond the control of either the ACD or the Depositary which mean that it is not possible or practicable to effect the Scheme. In these circumstances, the ACD and the Depositary will, with the approval of the FCA, continue to operate the Merging Fund until such time as it is practicable to effect the Merger which will be done on the terms of the Scheme with such consequential adjustments to the timetable as the ACD and the Depositary consider appropriate.

12.3 The terms of the Scheme may be amended as agreed by the ACD and the Depositary and approved by the FCA.

13. **Additional Information**

Please note that Shareholders will not have cancellation rights in respect of the New Shares which are issued to them under the Scheme. Under the provisions of The FCA Conduct of Business Sourcebook, cancellation rights may apply to subsequent purchases of shares.

14. **Governing law**

The Scheme is governed by, and shall be construed in accordance with, the laws of England and Wales.

APPENDIX 3: SHAREHOLDER NOTICE

NOTICE OF EXTRAORDINARY GENERAL MEETING

Notice is hereby given that a meeting of the shareholders in the Allianz European Equity Income Fund (the "Fund"), a sub-fund of Allianz UK & European Investment Funds (the "Company") will be held at the offices of Allianz Global Investors GmbH (acting by its UK branch) (the "ACD") at 199 Bishopsgate, London EC2M 3TY on 17 September 2021 at 12 noon to consider and, if thought fit, to pass the following extraordinary resolution.

EXTRAORDINARY RESOLUTION

THAT the scheme of arrangement for the merger of the Fund into the Allianz UK Listed Equity Income Fund, another sub-fund of the Company, the terms of which are set out in a circular dated 16 August 2021 and addressed by the ACD to shareholders in the Fund (the "Scheme") be and is hereby approved and adopted and accordingly that the ACD be and is hereby authorised to implement and give effect to the Scheme in accordance with its terms.

For and on behalf of Allianz Global Investors GmbH (acting by its UK branch)

(Authorised Corporate Director of the Company)

Authorised Signatory

Allianz Global Investors GmbH (acting by its UK branch)

16 August 2021

NOTES:

1. Any shareholder entitled to attend and vote may appoint a proxy (who need not be another shareholder) to attend and vote instead of them.
2. A proxy form is enclosed. The quorum for a meeting without adjournment is two shareholders present in person or by proxy (or, if a corporation, by duly authorised representative). Shareholders are asked to complete and return the proxy form so as to arrive no later than 5.00 pm on 13 September 2021. Any authority under which the proxy form is signed (or a certified copy thereof) should be sent with the proxy form. You should note that you may still attend and vote at the meeting.
3. On a show of hands, every shareholder who (being an individual) is present in person or by proxy or (being a corporation) is present by one of its officers as its representative shall have one vote. On a poll, shareholders may vote in person or by proxy. A shareholder entitled to more than one vote need not, if he votes, use all his votes or cast all his votes he uses, in the same way. On a poll, an extraordinary resolution will be passed if supported by a majority consisting of not less than 75% of the total number of votes cast for and against such extraordinary resolution.
4. If a quorum is not present within half an hour after the time appointed for the meeting, the meeting will be adjourned to 24 September 2021. This notice shall be deemed to constitute due notice of any such adjourned meeting. If a quorum is not present within fifteen minutes from the time appointed for the meeting, the shareholders present in person or by proxy will constitute a quorum irrespective of the number and value of shares held by them.

APPENDIX 4: CONSENTS AND CLEARANCES ETC

1. The ACD

The ACD confirms that in its opinion, the receipt of property under the Scheme by the Absorbing Fund will be consistent with the investment objectives of the Absorbing Fund and can be effected without any breach of Chapter 5 of the COLL Sourcebook. In addition, the ACD confirms that in its opinion, if the Scheme is implemented it is not likely to result in any material prejudice to the Shareholders in the Merging Fund or the Absorbing Fund.

2. **The Depositary**

State Street Trustees Limited as the Depositary of the Company has confirmed that, while making no recommendation or offering any opinion on the fairness or the merits of the Scheme, as such, which are matters for the judgement of each Shareholder in the Merging Fund, it consents to the references to it in this circular in the form and context in which they appear.

3. **FCA Consent**

The FCA have confirmed that the implementation of the Proposals will not affect the ongoing authorisation of the Company.

4. **HMRC Clearance**

For the proposed arrangements to be treated as a scheme of reconstruction for UK tax purposes under section 103H Taxation of Chargeable Gains Act 1992, with the consequence that such proposed arrangements should not result in a disposal for UK tax purposes, the proposed arrangements must be effected for bona fide commercial reasons and not have as their main purpose, or one of their main purposes, the avoidance of tax. There is a statutory procedure (under section 138 of the Taxation of Chargeable Gains Act 1992) for obtaining advance clearance from HMRC that this test is satisfied. The ACD has made an application for such clearance and HMRC has notified the ACD that the proposed arrangements satisfy this test.

The ACD has, at the same time, applied for clearance under section 748 Corporation Tax Act 2010 and section 701 Income Tax Act 2007 and HMRC has notified the ACD that clearance has been granted.

5. **Scheme to be Binding**

If the Extraordinary Resolution is passed at the Meeting, then the Scheme will be binding on all Shareholders whether or not they voted in favour of it or voted at all.

6. **Meeting of Shareholders**

The Meeting is being called for 17 September 2021. The notice of the Meeting is set out at Appendix 3. The notice sets out the Extraordinary Resolution to be proposed at the Meeting. For the purposes of determining the quorum and voting rights as set out below "Shareholders" means persons who were entered on the Register of Shareholders on 26 July 2021.

A majority of not less than 75% of the total number of votes cast is required to pass the Extraordinary Resolution. The quorum for the Meeting is two Shareholders present in person or by proxy.

If, within half an hour from the appointed time for the Meeting, a quorum is not present, then the Meeting will be adjourned to 24 September 2021. This notice shall be deemed to constitute due notice of any such adjourned meeting. If a quorum is not present within fifteen minutes from the time appointed for the Meeting, any one person entitled to be counted in the quorum shall constitute a quorum. Proxy Forms completed for use at the Meeting will remain valid for any adjourned meeting.

To avoid the expense and inconvenience of calling an adjourned meeting, Shareholders are asked to complete the enclosed Proxy Form and return it so as to be received no later than 5.00 pm on 13 September 2021.

This will not preclude Shareholders from attending and voting in person at the Meeting.

Neil Brown has been appointed as Chairman of the Meeting. The ACD is entitled to attend the Meeting but shall not be entitled to vote or be counted in a quorum at the Meeting nor any adjournment thereof, except that the ACD can vote and count in the quorum in respect of Shares which it holds on behalf of or jointly with a person who, if they themselves are the sole registered holder, would be entitled to vote, and from whom the ACD has received voting instructions. If the registered holder of any Shares is an associate of the ACD, that associate will only be entitled to exercise voting rights in respect of Shares held by it on behalf of a person who, if they themselves had been the registered holder, would have been entitled to vote, and from whom voting

instructions have been received. Associates of the ACD holding Shares are in any event entitled to be counted in a quorum.

In view of the importance of the Extraordinary Resolution the vote will be taken by poll.

On a poll, each Share will carry that proportion of the total number of votes exercisable in respect of Shares as is equal to the proportion which the price of one Share bears to the aggregate price of all Shares in issue. A Shareholder entitled to more than one vote need not, if they vote, use all of their votes or cast all their votes in the same way.

7. Documents available for inspection

Copies of the following documents are available for inspection during usual business hours on any business day at the offices of Allianz Global Investors GmbH (acting by its UK branch) at 199 Bishopsgate, London EC2M 3TY until the date of the Meeting (or up to and including the date of any adjourned meeting):

- 7.1 The Prospectus in respect of the Company;
- 7.2 The Instrument of Incorporation of the Company;
- 7.3 The most recent annual and half yearly reports of the Company;
- 7.4 The following letters referred to above:
 - (A) the letter from the FCA;
 - (B) the letter from HM Revenue & Customs;
- 7.5 The OEIC Regulations and the FCA Rules; and
- 7.6 The KIID for C Class Shares in the Absorbing Fund.

APPENDIX 5: GLOSSARY OF TERMS USED IN THIS DOCUMENT

“Absorbing Fund”	Allianz UK Listed Equity Income Fund.
“ACD”	Allianz Global Investors GmbH (acting by its UK branch) as the Authorised Corporate Director of the Merging Fund and the Absorbing Fund.
“Act”	The Financial Services and Markets Act 2000.
“Class or Classes”	means (according to the context) a particular class or classes of Shares.
“COLL Sourcebook”	The Collective Investment Schemes Sourcebook issued by the FCA as amended from time to time.
“Company”	Allianz International Investment Funds, an open-ended investment company structured as an umbrella company, under which the Merging and Absorbing Funds are established.
“Depositary”	State Street Trustees Limited.
“Effective Date”	The implementation date of the Scheme which is expected to be 1 October 2021 (or such other date as may be agreed between the ACD and the Depositary).
“Existing Share(s)”	A Class Shares and C Class Shares in the Merging Fund.
“Extraordinary Resolution”	The extraordinary resolution to approve the Merger, which Shareholders will be asked to pass at the Meeting.
“FCA”	The Financial Conduct Authority.
“FCA Rules”	The rules contained in the COLL Sourcebook.
“Instrument”	The current instrument of incorporation of the Company. An instrument of incorporation is the legal document that constitutes an OEIC.
“Meeting”	The extraordinary general meeting of the Shareholders to approve the Scheme, the notice for which is contained in Appendix 3.
“Merger”	The merger of the Merging Fund into the Absorbing Fund, on the Effective Date, effected by way of the Scheme and more particularly, the merger of A Class Shares and C Class Shares in the Merging Fund into C Class Shares in the Absorbing Fund.
“Merging Fund”	Allianz UK Listed Equity Income Fund.
“New Share(s)”	C Class Shares in the Absorbing Fund.
“OEIC”	An Open Ended Investment Company incorporated pursuant to Regulation 3 of the OEIC Regulations following its authorisation by the FCA.
“OEIC Regulations”	The Open Ended Investment Companies Regulations 2001, as amended.
“Proposals”	The proposals described in this circular including, without limitation, the Scheme and the Merger.
“Prospectus”	The prospectus of the Company.
“Proxy Form”	The form of proxy enclosed with this circular, to be completed in accordance with the instructions printed on it.

“Quorum”	The minimum number of Shareholders present in person or by proxy required for the Meeting to be valid.
“Required Majority”	The majority required by the FCA Rules to be validly cast in favour of the Extraordinary Resolution being at least 75% of the total number of votes cast.
“Retained Amount”	For the purposes of the Scheme, in relation to the Merging Fund, the amount which is calculated by the ACD (after consultation with the auditors of the Company) to be necessary to meet the actual and contingent liabilities (including distributable income, if any) retained by the Merging Fund. This amount is to be retained by the Depositary for the purpose of discharging those liabilities.
“Scheme”	The scheme of arrangement for the Merger of the Merging Fund into the Absorbing Fund, details of which are set out in Appendix 2.
“Share(s)”	Either Existing Share(s) or New Share(s), as the context may require.
“Shareholder”	A holder of Shares in the Merging Fund.
“Value”	The value of each of the Merging Fund or the Absorbing Fund or the Shares therein, as the context requires.

Where relevant in the context, terms which are defined in the Glossary of the FCA’s Handbook of Rules and Guidance of the OEIC Regulations shall have the same meaning in this circular.

Proxy form – Your vote is important, please use this form to vote on the scheme of arrangement in respect of your holding in Allianz European Equity Income Fund A Acc shares



Form of Proxy

For use at the **Extraordinary General Meeting** of shareholders of Allianz European Equity Income Fund (“the Fund”), to be held at the offices of Allianz Global Investors GmbH acting by its UK branch, 199 Bishopsgate, London, EC2M 3TY on 17 September 2021 at 12:00 noon and at any adjournment thereof.

Your Account No:

No. of Shares Held:

I direct my proxy to vote as follows in respect of the Resolution:

I/we the undersigned (of the above address) being a shareholder(s) in the Fund hereby appoint the Chairman of the meeting or, in his/ her absence, (see Note 1 overleaf) to act as my proxy at the meeting of shareholders of the Fund to be held at 12 noon on 17 September 2021 (and at any adjournment thereof) and to vote for me in my name on the extraordinary resolution set out in the Notice of Meeting indicated below:

THAT the proposal for the scheme of arrangement for the merger of the Fund into the Allianz UK Listed Equity Income Fund, both sub-funds of Allianz UK & European Investment Funds, the terms of which are set out in a circular dated 16 August 2021 and addressed by Allianz Global Investors GmbH (the “ACD”) to shareholders in the Fund be and is hereby approved and adopted and accordingly that the ACD be and is hereby authorised to implement and give effect to the proposal in accordance with its terms.

FOR AGAINST

Please place your vote in one of the boxes (a tick or a cross is acceptable).

If you wish to attend the meeting on 17 September 2021 at 12 noon please mark here:

Please complete, sign and return this proxy to us as soon as possible and in any event no later than 5.00 pm on 13 September 2021. A reply paid envelope is enclosed.

Signature(s):

Dated:

Notes:

1. A Shareholder entitled to attend and vote may appoint a proxy, who need not be another Shareholder of the Fund, to attend and vote on their behalf. Forms of proxy and the power of attorney or other authority (if any) under which they are signed (or a notarially certified copy thereof) must be deposited with Allianz Global Investors GmbH, c/o Paragon Customer Communications, PO Box 1408, Sunderland, SR5 9QY not later than 5.00 pm on 13 September 2021. Please use the reply-paid envelope provided.
2. To be passed, the resolution must be carried by a simple majority in favour of 75% or more of the votes validly cast for and against the resolution at the meeting.
3. On a poll, votes may be given personally or by proxy, and the voting rights attached to each share shall be such proportion of the voting rights attached to all of the shares in issue as the price of the share bears to the aggregate price(s) of all the shares in issue on the date seven days before the notice of meeting is deemed to have been served.
4. The quorum for the meeting is two Shareholders present in person or by proxy. If a quorum is not present within half an hour after the time appointed for the meeting, the meeting will be adjourned to 24 September 2021. This notice shall be deemed to constitute due notice of any such adjourned meeting. If at such adjourned meeting a quorum is not present within fifteen minutes from the time appointed for the meeting, one person entitled to be counted in a quorum at the meeting shall be a quorum.
5. In notes 1 to 4 above the expression "Shareholder" means persons who were entered on the Register of Shareholders on 26 July 2021 but excluding persons who are known to Allianz Global Investors GmbH not to be Shareholders in the Fund at the time of the meeting and the expression "Shareholder" should be construed accordingly.

Proxy form – Your vote is important, please use this form to vote on the scheme of arrangement in respect of your holding in Allianz European Equity Income Fund A Inc shares



Form of Proxy

For use at the **Extraordinary General Meeting** of shareholders of Allianz European Equity Income Fund (“the Fund”), to be held at the offices of Allianz Global Investors GmbH acting by its UK branch, 199 Bishopsgate, London, EC2M 3TY on 17 September 2021 at 12:00 noon and at any adjournment thereof.

Your Account No:
No. of Shares Held:

I direct my proxy to vote as follows in respect of the Resolution:

I/we the undersigned (of the above address) being a shareholder(s) in the Fund hereby appoint the Chairman of the meeting or, in his/ her absence, (see Note 1 overleaf) to act as my proxy at the meeting of shareholders of the Fund to be held at 12 noon on 17 September (and at any adjournment thereof) and to vote for me in my name on the extraordinary resolution set out in the Notice of Meeting indicated below:

THAT the proposal for the scheme of arrangement for the merger of the Fund into the Allianz UK Listed Equity Income Fund, both sub-funds of Allianz UK & European Investment Funds, the terms of which are set out in a circular dated 16 August 2021 and addressed by Allianz Global Investors GmbH (the “ACD”) to shareholders in the Fund be and is hereby approved and adopted and accordingly that the ACD be and is hereby authorised to implement and give effect to the proposal in accordance with its terms.

FOR AGAINST *Please place your vote in one of the boxes (a tick or a cross is acceptable).*

If you wish to attend the meeting on 17 September 2021 at 12 noon please mark here:

Please complete, sign and return this proxy to us as soon as possible and in any event no later than 5.00 pm on 13 September 2021. A reply paid envelope is enclosed.

Signature(s):

Dated:

Notes:

1. A Shareholder entitled to attend and vote may appoint a proxy, who need not be another Shareholder of the Fund, to attend and vote on their behalf. Forms of proxy and the power of attorney or other authority (if any) under which they are signed (or a notarially certified copy thereof) must be deposited with Allianz Global Investors GmbH, c/o Paragon Customer Communications, PO Box 1408, Sunderland, SR5 9QY not later than 5.00 pm on 13 September 2021. Please use the reply-paid envelope provided.
2. To be passed, the resolution must be carried by a simple majority in favour of 75% or more of the votes validly cast for and against the resolution at the meeting.
3. On a poll, votes may be given personally or by proxy, and the voting rights attached to each share shall be such proportion of the voting rights attached to all of the shares in issue as the price of the share bears to the aggregate price(s) of all the shares in issue on the date seven days before the notice of meeting is deemed to have been served.
4. The quorum for the meeting is two Shareholders present in person or by proxy. If a quorum is not present within half an hour after the time appointed for the meeting, the meeting will be adjourned to 24 September 2021. This notice shall be deemed to constitute due notice of any adjourned meeting. If at such adjourned meeting a quorum is not present within fifteen minutes from the time appointed for the meeting, one person entitled to be counted in a quorum at the meeting shall be a quorum.
5. In notes 1 to 4 above the expression "Shareholder" means persons who were entered on the Register of Shareholders on 26 July 2021 but excluding persons who are known to Allianz Global Investors GmbH not to be Shareholders in the Fund at the time of the meeting and the expression "Shareholder" should be construed accordingly.

Proxy form – Your vote is important, please use this form to vote on the scheme of arrangement in respect of your holding in Allianz European Equity Income Fund C Acc shares

Form of Proxy

For use at the **Extraordinary General Meeting** of shareholders of Allianz European Equity Income Fund (“the Fund”), to be held at the offices of Allianz Global Investors GmbH acting by its UK branch, 199 Bishopsgate, London, EC2M 3TY on 17 September 2021 at 12:00 noon and at any adjournment thereof.

Your Account No:

No. of Shares Held:

I direct my proxy to vote as follows in respect of the Resolution:

I/we the undersigned (of the above address) being a shareholder(s) in the Fund hereby appoint the Chairman of the meeting or, in his/ her absence, (see Note 1 overleaf) to act as my proxy at the meeting of shareholders of the Fund to be held at 12 noon on 17 September 2021 (and at any adjournment thereof) and to vote for me in my name on the extraordinary resolution set out in the Notice of Meeting indicated below:

THAT the proposal for the scheme of arrangement for the merger of the Fund into the Allianz UK Listed Equity Income Fund, both sub-funds of Allianz UK & European Investment Funds, the terms of which are set out in a circular dated 16 August 2021 and addressed by Allianz Global Investors GmbH (the “ACD”) to shareholders in the Fund be and is hereby approved and adopted and accordingly that the ACD be and is hereby authorised to implement and give effect to the proposal in accordance with its terms.

FOR AGAINST *Please place your vote in one of the boxes (a tick or a cross is acceptable).*

If you wish to attend the meeting on 17 September 2021 at 12 noon please mark here:

Please complete, sign and return this proxy to us as soon as possible and in any event no later than 5.00 pm on 13 September 2021. A reply paid envelope is enclosed.

Signature(s):
2021

Dated:

Notes:

1. A Shareholder entitled to attend and vote may appoint a proxy, who need not be another Shareholder of the Fund, to attend and vote on their behalf. Forms of proxy and the power of attorney or other authority (if any) under which they are signed (or a notarially certified copy thereof) must be deposited with Allianz Global Investors GmbH, c/o Paragon Customer Communications, PO Box 1408, Sunderland, SR5 9QY not later than 5.00 pm on 13 September 2021. Please use the reply-paid envelope provided.
2. To be passed, the resolution must be carried by a simple majority in favour of 75% or more of the votes validly cast for and against the resolution at the meeting.
3. On a poll, votes may be given personally or by proxy, and the voting rights attached to each share shall be such proportion of the voting rights attached to all of the shares in issue as the price of the share bears to the aggregate price(s) of all the shares in issue on the date seven days before the notice of meeting is deemed to have been served.
4. The quorum for the meeting is two Shareholders present in person or by proxy. If a quorum is not present within half an hour after the time appointed for the meeting, the meeting will be adjourned to 24 September 2021. This notice shall be deemed to constitute due notice of any adjourned meeting. If at such adjourned meeting a quorum is not present within fifteen minutes from the time appointed for the meeting, one person entitled to be counted in a quorum at the meeting shall be a quorum.
5. In notes 1 to 4 above the expression "Shareholder" means persons who were entered on the Register of Shareholders on 26 July 2021 but excluding persons who are known to Allianz Global Investors GmbH not to be Shareholders in the Fund at the time of the meeting and the expression "Shareholder" should be construed accordingly.

Proxy form – Your vote is important, please use this form to vote on the scheme of arrangement in respect of your holding in Allianz European Equity Income Fund C Inc shares



Form of Proxy

For use at the **Extraordinary General Meeting** of shareholders of Allianz European Equity Income Fund (“the Fund”), to be held at the offices of Allianz Global Investors GmbH acting by its UK branch, 199 Bishopsgate, London, EC2M 3TY on 17 September 2021 at 12:00 noon and at any adjournment thereof.

Your Account No:
No. of Shares Held:

I direct my proxy to vote as follows in respect of the Resolution:

I/we the undersigned (of the above address) being a shareholder(s) in the Fund hereby appoint the Chairman of the meeting or, in his/ her absence, (see Note 1 overleaf) to act as my proxy at the meeting of shareholders of the Fund to be held at 12 noon on 17 September 2021 (and at any adjournment thereof) and to vote for me in my name on the extraordinary resolution set out in the Notice of Meeting indicated below:

THAT the proposal for the scheme of arrangement for the merger of the Fund into the Allianz UK Listed Equity Income Fund, both sub-funds of Allianz UK & European Investment Funds, the terms of which are set out in a circular dated 16 August 2021 and addressed by Allianz Global Investors GmbH (the “ACD”) to shareholders in the Fund be and is hereby approved and adopted and accordingly that the ACD be and is hereby authorised to implement and give effect to the proposal in accordance with its terms.

FOR AGAINST *Please place your vote in one of the boxes (a tick or a cross is acceptable).*

If you wish to attend the meeting on 17 September 2021 at 12 noon please mark here:

Please complete, sign and return this proxy to us as soon as possible and in any event no later than 5.00 pm on 13 September 2021. A reply paid envelope is enclosed.

Signature(s):
2021

Dated:

Notes:

1. A Shareholder entitled to attend and vote may appoint a proxy, who need not be another Shareholder of the Fund, to attend and vote on their behalf. Forms of proxy and the power of attorney or other authority (if any) under which they are signed (or a notarially certified copy thereof) must be deposited with Allianz Global Investors GmbH, c/o Paragon Customer Communications, PO Box 1408, Sunderland, SR5 9QY not later than 5.00 pm on 13 September 2021. Please use the reply-paid envelope provided.
2. To be passed, the resolution must be carried by a simple majority in favour of 75% or more of the votes validly cast for and against the resolution at the meeting.
3. On a poll, votes may be given personally or by proxy, and the voting rights attached to each share shall be such proportion of the voting rights attached to all of the shares in issue as the price of the share bears to the aggregate price(s) of all the shares in issue on the date seven days before the notice of meeting is deemed to have been served.
4. The quorum for the meeting is two Shareholders present in person or by proxy. If a quorum is not present within half an hour after the time appointed for the meeting, the meeting will be adjourned to 24 September 2021. This notice shall be deemed to constitute due notice of any adjourned meeting. If at such adjourned meeting a quorum is not present within fifteen minutes from the time appointed for the meeting, one person entitled to be counted in a quorum at the meeting shall be a quorum.
5. In notes 1 to 4 above the expression "Shareholder" means persons who were entered on the Register of Shareholders on 26 July 2021 but excluding persons who are known to Allianz Global Investors GmbH not to be Shareholders in the Fund at the time of the meeting and the expression "Shareholder" should be construed accordingly.